ERBB2 and neoplasm: According to the American Society of Clinical Oncology—College of American Pathologists (ASCO–CAP) guidelines, the HER2-enriched subtype includes tumors that display HER2 positivity in ≥10% of tumor cells or exhibit HER2 gene amplification [4].